If I buy a product labelled NAD+, am I actually swallowing NAD+?

In most cases no. The intact NAD+ dinucleotide (molecular weight 663 daltons) is poorly orally bioavailable: it is partially hydrolysed in stomach acid, cleaved by intestinal NADase enzymes into smaller fragments such as NR, NMN, and niacinamide, and further degraded in hepatic first-pass metabolism. Most "NAD+" products on the market are in fact NR, NMN, or niacinamide once you read the supplement-facts panel.

Does intravenous NAD+ have strong human evidence?

No large double-blind randomised controlled trial of intravenous NAD+ is currently indexed in PubMed for any clinical indication. The frequently cited 1961 OHollaren report is a historical case series that does not meet modern randomised-trial standards. The FDA, EFSA, and ANVISA have not approved intravenous NAD+ for any clinical indication. Functional-medicine clinic protocols often combine NAD+ with B vitamins, minerals, and glutathione, which makes any single-component attribution difficult.

Is NAD+ decline with age a real phenomenon?

Yes. NAD+ concentrations decline measurably with age across multiple human tissues — for example skin NAD+ at 50 is approximately half the level at 20 (review PMID 39326681), and skeletal-muscle NAD+ in adults over 70 is reduced by 30 to 50 percent compared with younger controls. The factual question is biological. The harder question is which intervention reliably reverses the decline at the tissue level in humans.

If direct NAD+ is poorly absorbed, why does anyone sell it?

Commercial branding often uses the word "NAD+" because it is the consumer-recognised end-state molecule. Read the supplement-facts panel: the actual active ingredient is typically NR, NMN, or niacinamide, which are precursors that re-enter the salvage pathway inside cells. The branding shortcut and the bioavailable molecule are not the same thing.

What is the evidence-supported way to raise NAD+ via oral supplements?

Use a precursor — NR or NMN — both of which have multiple randomised controlled trials demonstrating that they raise blood NAD+ to approximately twice baseline at doses of 250 to 1000 mg per day. Niacinamide also raises NAD+ via the same salvage pool and has the strongest single trial (ONTRAC NEJM 2015) for non-melanoma skin cancer reduction. NADH has 25-plus years of human safety data and modest randomised evidence in chronic fatigue and jet-lag cognition.

How does NADH differ from NAD+ as a supplement strategy?

NADH is the reduced cofactor form — structurally NAD+ with an added hydride at the nicotinamide ring. NADH is not a precursor and not interconvertible by simple oral dosing into a higher NAD+ pool. It is the operative electron donor at mitochondrial Complex I. Stabilised oral NADH at 5 to 20 mg per day has randomised data in chronic fatigue (Forsyth 1999) and jet-lag cognition (Birkmayer 2002).

Should I do an intravenous NAD+ infusion at a functional-medicine clinic?

There is no large double-blind randomised controlled trial supporting routine clinical use of intravenous NAD+ infusion for any indication. If you are considering it, talk to a physician who is independent of the clinic selling the protocol. Do not treat user experience reports or testimonials as substitute for randomised evidence.

What is the regulatory status of NAD+ direct supplementation in the United States, the European Union, and Brazil?

In the United States, direct oral NAD+ as a discrete ingredient has no clear regulatory pathway, and what is sold is typically the precursors. Intravenous NAD+ is used in functional-medicine settings but is not FDA-approved for any indication. In the European Union, neither oral NAD+ nor intravenous NAD+ has authorised health claims, and direct NAD+ has no Novel Food authorisation. In Brazil, ANVISA has no specific approval pathway for direct NAD+ supplementation; NMN is specifically prohibited under ANVISA RE 1139/2022.

Will raising NAD+ make me live longer?

No human study has measured lifespan as an endpoint for any NAD+ precursor or for intact NAD+. Animal lifespan studies exist in mice; they do not transfer onto human use. The defensible framing is that raising NAD+ is one of several factors that may support cellular function, with documented effects on selected functional endpoints in older adults and amateur athletes for NMN specifically.

Why does this hub focus on the United States, European Union, and Brazil rather than on China?

This educational hub serves an international audience under the United States, European Union, and Brazil regulatory frameworks. The Chinese regulatory environment for NAD+ precursors is not the focus of this hub, and content here does not adjust for the Chinese regulatory framework.

NAD+ Direct Supplementation · Background and Evidence Limits

When most consumers search for "NAD+ supplement", what they actually purchase is rarely intact NAD+. The 663-dalton nicotinamide adenine dinucleotide molecule is poorly absorbed by mouth — degraded in stomach acid and cleaved by intestinal NADase enzymes into smaller fragments (NR, NMN, niacinamide) before absorption. As of 2026 there is no large double-blind randomised controlled trial demonstrating that oral intact NAD+ raises blood NAD+ in humans more reliably than its precursors do, and PubMed contains no large randomised trial of intravenous NAD+. This page explains the bioavailability problem, sets out what intravenous NAD+ data actually look like, and points readers toward the evidence-supported alternatives (NR, NMN, NADH).

1. Three Questions in Sixty Seconds

1.1 Does swallowing intact NAD+ work?

As of 2026, there is no large double-blind randomised controlled trial demonstrating that oral intact NAD+ raises blood NAD+ in humans more reliably than its precursors do. The reason is mechanical and biochemical, not ideological: NAD+ is a 663-dalton dinucleotide with two phosphate groups; it is partially hydrolysed in stomach acid (which sits at pH 1–2), cleaved by intestinal NADase enzymes into smaller fragments (NR, NMN, niacinamide) before enterocyte absorption, and further degraded in hepatic first-pass metabolism. The molecule that arrives in peripheral blood is not the molecule that was swallowed.

1.2 What about intravenous NAD+?

A PubMed search for double-blind randomised controlled trials of intravenous NAD+ in humans returns no large studies for any indication as of 2026-05-26. The historical literature includes 1960s-era case reports and small open-label cohorts, often combined with B vitamins, minerals, and glutathione in functional-medicine clinic protocols. The FDA, EFSA, and ANVISA have not approved intravenous NAD+ infusion for any clinical indication. This is not a statement that intravenous NAD+ is harmful; it is a statement that the evidence base for routine clinical decision-making is currently thin.

1.3 Is age-related NAD+ decline real, and what should I do about it?

NAD+ decline with age is a robust finding across multiple human tissues — skin (PMID 39326681 review, 50-year-old skin NAD+ at approximately half the 20-year-old level), skeletal muscle (30 to 50 percent reduction in adults over 70), and brain (PMID 39422945 review of NAD+/NADH ratio changes in older brain). The defensible response is precursor supplementation (NR, NMN) that re-enters the salvage pathway and reconstitutes the dinucleotide pool, or NADH supplementation that directly delivers reduced cofactor to mitochondrial Complex I. Direct intact NAD+ supplementation is not the evidence-supported route.

2. The Bioavailability Problem in Detail

NAD+ (nicotinamide adenine dinucleotide, oxidised form, PubChem CID 5893) is a dinucleotide of nicotinamide and adenine linked through two ribose sugars and two phosphate groups. The molecular formula is C21H27N7O14P2 and the molecular weight is 663.43 g/mol. Two physicochemical properties matter for oral supplementation:

High polarity. The two phosphate groups make NAD+ highly water-soluble and poorly lipid-soluble. Cell membranes are phospholipid bilayers; crossing one requires either an active transporter or local hydrolysis-then-resynthesis. Mammalian cells do not have a dedicated NAD+ uptake transporter that is well characterised at plasma-membrane level for the intact dinucleotide. The main intracellular route is via smaller fragments — NR enters via ENT/CNT nucleoside transporters and is rephosphorylated to NMN by NRK1 (PMID 27725675), and then to NAD+ by NMNAT.

Chemical instability. NAD+ at stomach pH (1–2) undergoes spontaneous hydrolysis, with the thermodynamics favouring decomposition to NMN and AMP. The integrity of an "NAD+ capsule" depends on enteric coating, gastric residence time, and post-absorption stability — and even with the best engineering, the molecule does not arrive in peripheral blood unchanged.

Three sequential degradation steps explain why oral intact NAD+ is poorly absorbed:

Stage	Location	What happens to intact NAD+
1 · Gastric hydrolysis	Stomach, pH 1–2	Spontaneous decomposition to NMN + AMP fragments.
2 · Intestinal NADase cleavage	Small intestine and colon	NAD+ is enzymatically cleaved by NADase enzymes (CD38, CD157/BST1) into NR, NMN, and niacinamide.
3 · Hepatic first-pass metabolism	Liver	Even fragments that survive the small intestine encounter further degradation by hepatic NADase before reaching the peripheral circulation.

The honest summary: the peripheral blood concentration of intact NAD+ after oral dosing is poorly characterised by human pharmacokinetic data. Compare with the human pharmacokinetics of NR (Trammell 2016 PMID 27721479) and NMN (Irie 2020 PMID 31685720; Yi 2022 PMID 36482258), both of which have multiple human PK studies demonstrating measurable elevation of blood NAD+ metabolome from oral dosing.

3. Intravenous NAD+ — What the Data Actually Look Like

3.1 What is often said in functional-medicine settings

Functional-medicine clinics frequently market intravenous NAD+ infusions at 250 to 1000 mg over 4 to 8 hours per session, often as a course of multiple sessions, for indications including general healthy ageing, post-substance-use recovery, and chronic fatigue. Costs are typically in the range of several hundred to a few thousand US dollars per protocol. The marketing rationale is that intravenous administration bypasses the oral bioavailability problem.

3.2 What PubMed actually contains

A 2026-05-26 PubMed search for "intravenous NAD+ infusion humans" restricted to randomised clinical trials returns zero large double-blind RCTs. The published intravenous NAD+ human literature consists of: historical case reports from the 1960s and 1970s (OHollaren and others) that do not meet modern randomised-trial standards; small pharmacokinetic studies with sample sizes under 10; and small open-label observational cohorts under 30 participants, frequently in substance-use-disorder settings, with intravenous NAD+ administered in combination with B vitamins, minerals, and glutathione. The FDA, EFSA, and ANVISA have not approved intravenous NAD+ for any clinical indication.

3.3 Three caveats that apply to existing intravenous NAD+ studies

Sample-size ceiling. The largest published intravenous NAD+ clinical studies have around n=30, are open-label, and would not qualify as A- or B-tier evidence under the GRADE framework.

Combination-protocol confound. Most functional-medicine clinic protocols combine intravenous NAD+ with B vitamins, minerals, and glutathione. Attribution to NAD+ specifically is statistically unfeasible in this design.

Pharmacokinetic gap. The actual intracellular NAD+ elevation in human tissue biopsies after intravenous NAD+ infusion is not well characterised. Plasma NAD+ elevation does not equal tissue NAD+ reconstitution — CD38 and other NADases continue to consume NAD+ at peripheral and tissue levels.

4. What Actually Works — The Precursor Routes

For consumers asking "How do I raise NAD+?", the evidence-supported answer is precursor supplementation. Three routes have substantial human randomised data:

4.1 NR (nicotinamide riboside)

NR is the precursor with the longest cumulative human RCT history. Trammell 2016 (PMID 27721479) is the landmark pharmacokinetics paper demonstrating that oral NR produces dose-dependent elevation of the blood NAD+ metabolome at 100, 300, and 1000 mg per day. Brakedal 2022 NADPARK in Parkinson disease (PMID 35235780) showed that NR raised brain NAD+ in PD patients. Bock 2024 NICE in peripheral artery disease (PMID 38871717, n=90, 1000 mg per day for 6 months) reported a six-minute walk-test improvement as a secondary endpoint. NR is GRAS in the United States (Niagen brand), Novel Food in the European Union with national variation, and case-by-case in Brazil.

4.2 NMN (β-nicotinamide mononucleotide)

NMN is one enzymatic step downstream of NR in the salvage pathway. Thirteen human RCTs (covered in detail on the dedicated NMN page) document approximately twofold blood NAD+ elevation at 250 to 1000 mg per day, functional improvements in older adults (walking speed, grip strength, sit-to-stand, sleep), and aerobic-capacity improvements in amateur runners. Regulatory status as of 2026: United States legal (after the 2025-09 FDA reversal), European Union under Novel Food evaluation, Brazil prohibited under ANVISA RE 1139/2022.

4.3 NADH (reduced nicotinamide adenine dinucleotide)

NADH is the reduced cofactor — not a precursor — and directly donates electrons at mitochondrial Complex I. Stabilised oral NADH at 5 to 20 mg per day has approximately 25 years of dietary-supplement marketing experience under DSHEA and modest randomised evidence in chronic fatigue (Forsyth 1999 PMID 10071523) and jet-lag cognitive performance (Birkmayer 2002 PMID 12385067). The CoQ10+NADH combination has additional RCT support in chronic fatigue syndrome (Castro-Marrero 2015 PMID 25386668). Read the dedicated NADH page for the full evidence base.

4.4 Side-by-side comparison

Strategy	Mechanism	Large human RCTs	Notable caveat
Direct oral NAD+	Intended to deliver intact dinucleotide	0 large double-blind RCTs	663-dalton polar molecule; degraded by gastric acid and intestinal NADase before absorption.
NR oral	Salvage pathway via NRK1/2	~11 large RCTs	Dollerup 2020 negative in obese insulin-resistant adults — honest mixed signal.
NMN oral	Salvage pathway via NRK1/NMNAT	~13 large RCTs	Brazil full-chain prohibition under ANVISA RE 1139/2022.
NADH oral (stabilised)	Direct Complex I electron donor	~6 placebo-controlled, mostly small	Sample sizes are small; never head-to-head with precursors.
Intravenous NAD+	Bypasses GI; intent is to elevate plasma NAD+	0 large double-blind RCTs	Sample sizes under 30, combination protocols, no regulator approval.

5. Transparent Reverse-Correction Disclosures

Five reverse-correction items, surfaced during the preparation of this page, are disclosed transparently:

R-1 · NAD+ decline causal-chain framing. Earlier dispatch material implied that NAD+ decline directly justifies "direct NAD+ supplementation." The defensible causal chain in human evidence runs through precursors (NR or NMN feed the salvage pathway, NAD+ pool reconstitutes), not through direct intact NAD+ supplementation. The page text in section 1.3 carries this corrected framing.
R-2 · NMN-to-NAD+ equivalence. Earlier dispatch material described NMN as "the direct precursor to NAD+" without flagging that NMN-to-NAD+ conversion requires NMNAT enzyme catalysis (and possibly SLC12A8-mediated transport, which is contested). The page text in section 4.2 references the NMN page for the full mechanism.
R-3 · Intravenous NAD+ "gold standard" framing. Earlier dispatch material suggested intravenous NAD+ is a "gold standard". This framing is not defensible under evidence-based medicine standards. The page text in section 3 presents intravenous NAD+ as a high-exposure-bypassing strategy without large randomised evidence and without regulatory approval for any indication.
R-4 · NADH equivalence to NAD+. Earlier dispatch material described NADH as a form of "direct NAD+ supplementation." NADH is the reduced cofactor, not a precursor, and is structurally distinct from NAD+. The page text in section 4.3 references the NADH page for the full distinction.
R-5 · Evidence-gap completeness. Earlier dispatch material noted only that "direct NAD+ evidence is sparse". The page text in section 3 expands this into a full evidence-gap section covering the sample-size ceiling, combination-protocol confound, and pharmacokinetic gap.

6. Use Cases Across Goals and Lifestyles

6.1 For the longevity stack reader

Direct NAD+ supplementation faces the bioavailability wall described in section 2. NAD+ pool decline with age is, however, a real anchor in longevity biology. The educational pathway is: read the consumer-relevant difference between "direct NAD+" and "precursor (NR or NMN)" supplementation, choose a precursor for which human RCT evidence exists, and reserve any consideration of intravenous NAD+ for a discussion with a physician who is independent of the clinic selling the protocol.

6.2 For the athletic performance reader and the athletic performance lifestyle

Skeletal-muscle NAD+ pool is one of the limiting factors for sustained oxidative ATP production. The athletic-performance evidence is on the NMN page (Liao 2021 amateur runners, dose-dependent aerobic capacity). One additional consideration in competitive contexts: intravenous NAD+ infusion may be viewed by some sport governance bodies as a metabolic modulator and could carry compliance risk during competition season — athletes should consult their sport-specific anti-doping authority for current guidance.

6.3 For the cognitive support reader

Neurodegenerative-disease research (Alzheimer disease, Parkinson disease, mild cognitive impairment) is one of the most active areas in NR clinical trial development. Brakedal 2022 NADPARK (PMID 35235780) demonstrated brain NAD+ elevation with NR in Parkinson disease patients; Vreones 2024 (PMID 37994989) reported sub-domain cognitive improvements with NR in mild cognitive impairment. Standard FDA DSHEA non-disease-claim language must apply to any consumer-facing communication.

6.4 For the heart health reader

The Bock 2024 NICE trial (PMID 38871717) in peripheral artery disease reported a six-minute walk-test improvement on NR; the NMN cardiovascular surrogate-endpoint trial Katayoshi 2023 (PMID 36797393) reported a non-significant trend toward reduced arterial stiffness. Direct NAD+ has no cardiovascular RCT evidence.

6.5 For the senior 60+ lifestyle

This is the lifestyle most affected by NAD+ decline. The densest evidence cluster is NMN at 250 to 500 mg per day (Yoshino 2021, Igarashi 2022, Kim 2022, Morita 2024). Competitive sport-level dosing (above 1000 mg per day) is not necessary in this lifestyle.

6.6 For the high-stress lifestyle

Chronic inflammation and sleep deprivation accelerate PARP1 and CD38 NAD+ consumption. NAD+ pool support via precursors can be considered as a baseline supplementation candidate, but should not be the primary stress-management intervention — behavioural changes (sleep, exercise, stress reduction) remain primary.

References

PMID 27721479 · Trammell SAJ et al. 2016 · Nat Commun · NR pharmacokinetics landmark.
PMID 27725675 · Ratajczak J et al. 2016 · Nat Commun · NRK1 controls NMN/NR metabolism.
PMID 34799586 · Wilk A et al. 2021 · Nat Commun · BST1/CD157 NR metabolism.
PMID 35235780 · Brakedal B et al. 2022 · Cell Metab · NADPARK NR brain NAD+ in Parkinson disease.
PMID 38871717 · Bock JM et al. 2024 · Nat Commun · NICE NR peripheral artery disease.
PMID 37994989 · Vreones M et al. 2024 · GeroScience · NR in mild cognitive impairment.
PMID 33888596 · Yoshino M et al. 2021 · Science · NMN postmenopausal RCT.
PMID 36482258 · Yi L et al. 2022 · GeroScience · NMN dose-finding.
PMID 36740954 · Pencina KM et al. 2023 · J Clin Endocrinol Metab · MIB-626.
PMID 35479740 · Okabe K et al. 2022 · Front Nutr · NMN 12-week RCT.
PMID 34238308 · Liao B et al. 2021 · NMN amateur runners.
PMID 35927255 · Igarashi M et al. 2022 · npj Aging · NMN older adults.
PMID 35215405 · Kim M et al. 2022 · Nutrients · NMN chronobiology.
PMID 36797393 · Katayoshi T et al. 2023 · Sci Rep · NMN arterial stiffness trend.
PMID 36002548 · Fukamizu Y et al. 2022 · Sci Rep · NMN safety 1250 mg/4wk.
PMID 39116016 · Zhang J et al. 2025 · Crit Rev Food Sci Nutr · meta-analysis 12 NMN RCTs.
PMID 10071523 · Forsyth LM et al. 1999 · NADH chronic fatigue RCT.
PMID 25386668 · Castro-Marrero J et al. 2015 · Antioxid Redox Signal · CoQ10+NADH CFS.
PMID 34444817 · Castro-Marrero J et al. 2021 · Nutrients · CoQ10+NADH CFS n=207.
PMID 39326681 · NAD+ homeostasis and exercise adaptation review · 2024.
PMID 39422945 · NAD+ Precursors for Alzheimer review · J Alzheimers Dis · 2024.
PMID 31685720 · Irie J et al. 2020 · NMN single-dose safety.

Educational Disclaimer

This page is educational reference content and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Discuss any supplement use, including any intravenous infusion protocol, with a qualified healthcare provider who is independent of any clinic selling the protocol. Regulatory status varies by jurisdiction; this hub focuses on the United States, the European Union, and Brazil.

← All Ingredients